You can buy or sell TTNP and other stocks, options, and ETFs commission-free!
Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA. The listed name for TTNP is Titan Pharmaceuticals, Inc. Common Stock.
Sunil Bhonsle, MBA
South San Francisco, California
52 Week High
52 Week Low
— per share
Expected Mar 30, Pre-Market